Absci (ABSI) Financials: History & Chart

Absci Corporation(ABSI)

Biotechnology · Vancouver, WA

$10.44-1.09 (-9.50%)

Delayed quote: Oct 6, 2026, 3:20 PM EDT

About Absci Corporation

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

Vancouver, WA

140 employees

www.absci.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sean McClain

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.56M	318K	215K	650K	378K	593K	1.18M	665K	1.70M
Cost of Goods Sold	5.56M	0.00	2.73M	2.83M	0.00	20.46M	16.36M	16.98M	3.35M
Gross Profit	-4.00M	318K	-2.51M	-2.18M	378K	-19.86M	-15.19M	-16.31M	-1.65M
Gross Profit Margin	-255.9%	100.0%	-1168.8%	-335.1%	100.0%	-3349.9%	-1288.0%	-2452.9%	-97.2%
Total Operating Expenses	127.31M	34.48M	28.33M	33.96M	30.53M	11.53M	12.54M	13.46M	27.24M
Research & Development	86.49M	22.62M	19.27M	25.35M	19.25M	20.46M	16.36M	18.38M	17.98M
Selling, General & Administrative	26.84M	9.16M	9.06M	8.62M	0.00	0.00	0.00	0.00	9.26M
Operating Income (EBIT)	-131.30M	-34.16M	-30.85M	-36.14M	-30.15M	-31.39M	-27.73M	-29.77M	-28.89M
Operating Margin	-8411.3%	-10741.5%	-14347.0%	-5560.3%	-7977.2%	-5293.9%	-2351.9%	-4477.3%	-1698.7%
Income Before Tax (EBT)	-121.08M	-33.17M	-29.58M	-29.72M	-28.60M	-30.44M	-26.35M	-28.96M	-27.36M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	58K	2K	-18K	29K	45K	56K	79K	109K	130K
Other Income/Expense	10.22M	988K	1.26M	6.42M	1.55M	955K	1.38M	812K	1.53M
Net Income	-121.08M	-33.21M	-29.60M	-29.56M	-28.71M	-30.57M	-26.35M	-28.98M	-27.40M
Income Tax Expense	0.00	40K	18K	-162K	104K	131K	-4K	21K	37K
Net Profit Margin	-7756.4%	-10443.4%	-13767.0%	-4548.0%	-7594.2%	-5155.0%	-2234.6%	-4358.3%	-1610.7%
EBITDA	-120.21M	-31.46M	-28.12M	-33.31M	-27.31M	-28.39M	-24.66M	-26.54M	-25.54M
EBITDA Margin	-7700.6%	-9893.7%	-13078.1%	-5125.2%	-7225.4%	-4788.0%	-2091.3%	-3991.0%	-1501.5%
Depreciation & Amortization	11.09M	2.70M	2.73M	2.83M	2.84M	3.00M	3.07M	3.23M	3.35M
EPS Basic	-0.80	-0.21	-0.19	-0.20	-0.20	-0.24	-0.21	-0.25	-0.24
EPS Diluted	-0.80	-0.21	-0.19	-0.20	-0.20	-0.24	-0.21	-0.25	-0.24
Weighted Average Basic Shares	157.47M	157.47M	152.96M	150.61M	143.77M	127.59M	124.46M	114.93M	113.61M
Weighted Average Diluted Shares	157.47M	157.47M	152.96M	150.61M	143.77M	127.59M	124.46M	114.93M	113.61M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenue	2.80M	4.53M	5.72M	5.75M	4.78M	4.78M	2.06M
Cost of Goods Sold	11.74M	62.46M	47.57M	58.91M	44.59M	11.45M	0.00
Gross Profit	-8.94M	-57.92M	-41.85M	-53.16M	-39.80M	-6.67M	2.06M
Gross Profit Margin	-319.4%	-1277.6%	-731.9%	-925.0%	-832.4%	-139.5%	100.0%
Total Operating Expenses	115.78M	50.96M	73.67M	53.59M	35.43M	6.63M	8.32M
Research & Development	81.42M	63.86M	48.07M	58.91M	44.59M	11.45M	4.31M
Selling, General & Administrative	35.06M	0.00	0.00	0.00	0.00	5.50M	3.52M
Operating Income (EBIT)	-124.72M	-108.89M	-115.52M	-106.75M	-75.24M	-13.30M	-6.26M
Operating Margin	-4454.2%	-2401.6%	-2020.2%	-1857.5%	-1573.4%	-278.3%	-304.1%
Income Before Tax (EBT)	-115.11M	-103.04M	-110.47M	-105.36M	-109.86M	-14.35M	-6.58M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	209K	565K	1.01M	972K	3.43M	634K	268K
Other Income/Expense	9.60M	5.85M	5.05M	1.39M	-34.62M	-1.05M	-319K
Net Income	-115.18M	-103.11M	-110.57M	-104.90M	-100.96M	-14.35M	-6.58M
Income Tax Expense	69K	70K	100K	-461K	-8.90M	0.00	0.00
Net Profit Margin	-4113.7%	-2274.1%	-1933.6%	-1825.4%	-2111.3%	-300.3%	-319.6%
EBITDA	-112.98M	-95.50M	-101.52M	-93.71M	-68.58M	-12.17M	-5.77M
EBITDA Margin	-4034.9%	-2106.3%	-1775.4%	-1630.6%	-1434.2%	-254.6%	-280.3%
Depreciation & Amortization	11.74M	13.39M	14.00M	13.04M	6.65M	1.13M	491K
EPS Basic	-0.84	-0.94	-1.20	-1.15	-1.11	-0.54	-0.07
EPS Diluted	-0.84	-0.94	-1.20	-1.15	-1.11	-0.54	-0.07
Weighted Average Basic Shares	136.78M	110.24M	92.03M	90.85M	92.65M	92.25M	92.25M
Weighted Average Diluted Shares	136.78M	110.24M	92.03M	90.85M	92.65M	92.25M	92.25M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.